Henry K, Schwebke K
HIV Program, St. Paul-Ramsey Medical Center.
Minn Med. 1993 Nov;76(11):17-23.
More than 300,000 cases of AIDS have been reported in the United States since 1981. Despite major scientific advances and much effort, the benefits of treatment have been modest. The variable nature of the human immunodeficiency virus (HIV) and the complexity of the immune system are the major obstacles to advances in treatment. This article summarizes the current state of clinical research in pursuit of improved HIV therapy and takes a look into the future of anti-HIV therapeutics. It also provides an overview of HIV clinical research underway in Minnesota. Research efforts to improve therapy of HIV-induced immune deficiency will involve three strategies: better anti-HIV drugs and combinations of drugs aimed at slowing the replication of HIV, immune-based therapies intended to stimulate the immune system, and multiple opportunistic pathogen prophylaxis strategies to prevent HIV-related opportunistic infections. This approach will involve considerable cost and polypharmacy. Improvements in HIV/AIDS therapy are likely to occur incrementally, but the endeavor needs widespread support from patients, physicians, and the public. For now, the best strategy is prevention, which is where physicians can have the greatest impact on the epidemic.
自1981年以来，美国已报告超过30万例艾滋病病例。尽管取得了重大科学进展并付出了诸多努力，但治疗效果仍较为有限。人类免疫缺陷病毒（HIV）的多变性以及免疫系统的复杂性是治疗进展的主要障碍。本文总结了当前为改进HIV治疗而进行的临床研究现状，并展望了抗HIV治疗的未来。它还概述了明尼苏达州正在进行的HIV临床研究。改善HIV诱导的免疫缺陷治疗的研究工作将涉及三种策略：更好的抗HIV药物以及旨在减缓HIV复制的药物组合、旨在刺激免疫系统的免疫疗法，以及预防HIV相关机会性感染的多种机会性病原体预防策略。这种方法将涉及相当高的成本和联合用药。HIV/AIDS治疗的改善可能会逐步实现，但这一努力需要患者、医生和公众的广泛支持。目前，最佳策略是预防，这也是医生对该流行病能产生最大影响的领域。
